NCT01715441View on ClinicalTrials.gov

Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

173

Participants

Timeline

Start Date

September 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

September 30, 2015

Conditions
Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors
Interventions
DRUG

Sorafenib and irinotecan combination

DRUG

Sorafenib monotherapy

DRUG

Irinotecan monotherapy

Trial Locations (9)

13365

Hôpital LA TIMONE, Marseille

14076

Centre François Baclesse, Caen

34298

CRLC Val d'Aurelle-Paul Lamarque, Montpellier

44805

Institut de Cancérologie de l'Ouest - René Gauducheau, Saint-Herblain

51092

C.H.U. de REIMS, Reims

59020

Centre Oscar Lambret, Lille

69373

Centre Léon Bérard, Lyon

76038

CHU Charles Nicolle, Rouen

93009

Hôpital AVICENNE, Bobigny

All Listed Sponsors
lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT01715441 - Sorafenib in Combination With Irinotecan in Metastatic Colorectal Cancer Patients With KRAS Mutated Tumors | Biotech Hunter | Biotech Hunter